SPONSORSHIP ALLIANCE NEWS
Radiosurgery (stereotactic body radiation therapy, SBRT) is considered a standard option in the treatment of spinal metastases.
You know the dilemma: effective pain relief and high tumor control are achievable today—yet the question remains of how to protect the spinal cord without compromise.
The Department of Radiation Oncology at Stanford University seeks a board eligible or board-certified radiation oncologist to join the Department in the Clinician Educator line (open rank). We are particularly interested in candidates who have interest and experience with treating gastrointestinal (GI) and genitourinary (GU) cancers.
Background:
Radiation necrosis (RN) is a recognized complication of stereotactic radiosurgery (SRS) for brain metastases, typically occurring within 6–24 months after treatment. Late RN occurring several years after SRS remains uncommon and may present substantial diagnostic challenges, particularly in patients with prolonged systemic immune exposure and evolving imaging abnormalities.
Decline of quality of life (QOL) and cognitive function is common for brain metastases patients receiving radiotherapy but there is currently no standard of care for addressing those symptoms. This phase 2 randomized controlled trial examined the efficacy of early neuropsychological evaluation and integration to preserve QOL and cognition for patients treated with radiation for brain metastases.
Advances in local and systemic therapy are continuously improving overall survival in cancer patients – yet at the same time, they are driving an increase in spinal metastases.
Milestone underscores growing clinical adoption of vault-free, cobalt-free stereotactic radiosurgery for advanced, patient-centered brain tumor treatment
We are pleased to invite submissions to our Special Issue in Cancers focused on innovative advances in neuro-oncology imaging and radiotherapy. Topics of interest include advanced MRI, amino acid PET, DOTATATE imaging, radiomics, AI applications, SRS/SBRT, proton therapy, FLASH radiotherapy, BNCT, re-irradiation, connectomics-guided radiotherapy, and other personalized treatment approaches for primary and metastatic CNS tumors. Original research, reviews, technical reports, and multidisciplinary perspectives are welcome.
Manuscript submission deadline: March 31, 2027
FLASH therapy is defined by ultra-rapid radiation delivery in a fraction of a second. Originally conceived to enhance precision by completing treatment before a patient's natural bodily movements occurred, the research has shifted following a major biological discovery.
Multicenter analysis: Radiosurgery proves to be an effective and safe option for pediatric lesions of the central nervous system (CNS)
Primary brain tumors account for approximately 20 to 27% of all tumors in children, making them the most common solid tumors in this patient group. [1-4]
Surgery, conventional radiation therapy, and systemic therapies are considered standard in pediatric neurooncology.
New findings from a multicenter registry show that stereotactic radiosurgery (SRS) with the CyberKnife treatment system is an important and effective option for pediatric CNS lesions, particularly when conventional treatments are limited. [5]
The Stanford Department of Neurosurgery is now accepting applications for the 2026-2027 Clinical Fellowship in Neurosurgical Oncology and Stereotactic Radiosurgery. Under the direction of Dr. Steven D. Chang, this one-year GME program offers specialized training in CyberKnife treatment planning and delivery for a diverse range of oncologic and functional conditions.
Interested applicants who have completed an ACGME-accredited residency within the U.S or have 24 of months of Board-approved postgraduate training should email their CV, personal statement, and three letters of recommendation to Dr. David J. Park at djpark@stanford.edu
About 40% of all men will develop prostate cancer during their lifetime, with over 65,000 new cases diagnosed annually in Germany [1]. Age is a key risk factor, as most cases occur in men aged 65 or older.
“With robot-guided stereotactic radiosurgery (SBRT), we are now able to treat localized prostate cancer – especially intermediate-risk cases – very effectively in many patients,” says Alexander Muacevic, MD, Director of the European Radiosurgery Center Munich (ERCM).
The completed HYPOSTAT-II trial, involving 464 participants – 249 of whom were treated at the ERCM – confirms that SBRT is well tolerated and associated with high patient satisfaction. Results to date are comparable to those of the PACE trials, whose findings contributed to the inclusion of radiosurgery in the German S3 clinical guidelines (the highest level of evidence-based medical guidelines in Germany) in 2025.
This study investigates long-term oncological outcomes of RS for upper tract urothelial carcinoma (UTUC) in patients unfit for surgery or with a solitary kidney.